AC Immune SA

ACIU Nasdaq SEC CIK 1651625
Follow AC Immune Weekly email: filings, results

Financials

Reported figures only · latest: Q4 2025 CHF · IFRS
EPS, diluted -
Revenue by quarter
CHF 687K
CHF 1.3M
Q2 24 Q2 25

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, IFRS
Revenue and net income12 fiscal years
  • Revenue
  • Net income
−CHF 100M−CHF 50MCHF 0CHF 50MCHF 100MCHF 150MFY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25CHF 3.6M−CHF 70.4M
FY24CHF 27.3M−CHF 50.9M
FY23CHF 14.8M−CHF 54.2M
FY22CHF 3.9M−CHF 70.8M
FY21CHF 0−CHF 73M
FY20CHF 15.4M−CHF 61.9M
FY19CHF 110.5MCHF 45.4M
FY18CHF 6.9M−CHF 51M
FY17CHF 20.3M−CHF 26.4M
FY16CHF 23.2M−CHF 7.1M
FY15CHF 39.1MCHF 20.3M
FY14--
MarginsShare of revenue
  • Operating margin
  • Net margin
−2000%−1000%0%1000%FY15FY17FY19FY21FY23FY25
Show the numbers
YearOperating marginNet margin
FY25−1940.1%−1971.6%
FY24−191.8%−186.4%
FY23−362.3%−366.4%
FY22−1800.4%−1798%
FY21--
FY20−397%−401.3%
FY1940.3%41.1%
FY18−716.9%−737.1%
FY17−111.3%−130.4%
FY16−45%−30.6%
FY1547.6%51.9%
FY14--
Free cash flowOperating cash flow minus capital expenditure
−CHF 100M−CHF 50MCHF 0CHF 50MCHF 100MFY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−CHF 70.2M
FY24CHF 65.3M
FY23−CHF 61.2M
FY22−CHF 74.8M
FY21−CHF 68.3M
FY20−CHF 61.2M
FY19CHF 53.3M
FY18−CHF 45.9M
FY17−CHF 23.9M
FY16−CHF 6.5M
FY15CHF 43.8M
FY14-
Returned to shareholdersDividends paid and shares bought back
CHF 0CHF 25KCHF 50KCHF 75KCHF 100KFY15FY17FY19FY21FY23FY25
Show the numbers
YearBuybacks
FY25-
FY24-
FY23-
FY22CHF 0
FY21CHF 0
FY20CHF 100K
FY19CHF 0
FY18CHF 0
FY17-
FY16-
FY15-
FY14-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • AC Immune
  • Healthcare median
−2000%−1000%0%1000%FY15FY17FY19FY21FY23FY25
Show the numbers
YearAC ImmuneHealthcare median
FY25−1971.6%−30.6%
FY24−186.4%−47%
FY23−366.4%−58%
FY22−1798%−80.4%
FY21-−71.9%
FY20−401.3%−62.2%
FY1941.1%−46.3%
FY18−737.1%−49.6%
FY17−130.4%−45.9%
FY16−30.6%−36%
FY1551.9%−38.4%
FY14-−35.5%